Latest News
Latest News
Prior authorization software: Saves time but hurdles remain
The automation works, but the software can be costly and may not work for all practices.
From the Journals
‘Diagnosis creep’: Are some AFib patients overtreated?
“Risk scores derived when risk variables were described in one way are starting to be applied based on a diagnosis made in a totally different way...
From the Journals
CKD linked to cardiac arrest in Hispanic, Latinx patients
“Our study, the first to include feasible numbers of Hispanic or Latino individuals, highlights the importance of renal dysfunction as a risk...
Conference Coverage
Trials say start sacubitril-valsartan in hospital in HF with ‘below normal’ LVEF
The risk-reduction benefit reached 41% among the overwhelming majority of patients with a left ventricular ejection fraction.
From the Journals
New tool to guide transcatheter aortic valve replacement
The study demonstrated the “notable feasibility and safety” of TJ-ICE–guided TAVR, the authors write.
Latest News
EMA warns that omega-3-acid ethyl esters may cause AFib
Experts found a dose-dependent increase in the risk for atrial fibrillation in patients with cardiovascular diseases or cardiovascular risk...
Latest News
High and low HDL cholesterol levels linked to dementia risk
There was no significant association between LDL cholesterol and dementia risk.
Conference Coverage
Hopeful insights, no overall HFpEF gains from splanchnic nerve ablation: REBALANCE-HF
The trial’s potential-responder cohort “seemed able to augment cardiac output in response to stress” and to “maintain or augment their orthostatic...
From the Journals
Pragmatic solutions to ‘catastrophic’ global stroke burden
Recommendations to reduce the global burden of stroke include measures to improve surveillance, prevention, acute care, and rehabilitation.
From the Journals
Alert! A decade of type 2 diabetes shortens life by 3.5 years
“I personally think the findings show that we should treat cardiovascular risk factors more aggressively in people diagnosed with [type 2]...
News from the FDA/CDC
FDA denies approval for patisiran in ATTR cardiomyopathy, despite panel nod
The FDA indicated in the letter that the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis have...